RT J Michael Waller (@JMichaelWaller)Washington Post & New York Times ran fake stories on December 9, 2016 that concluded that an Intelligence Community Assessment (ICA) had high confidence that Russia intervened to help Trump win the election. "The Post cited an unnamed US official as saying that this was the "consensus view."Yet when the stories were posted, the intelligence community had not had its meeting yet to provide that "consensus view." The President's Daily Brief had been spiked the day before.T ...

Read our blog to learn how Ethereum is redefining digital trust through Trustware: https://t.co/LIcrzjwBOi ...

The Industrial Revolution improved everyone’s life, in the long run.But in the medium run, it caused the rise of communism, the murder of capitalists, and the advent of world war. Technological advance caused political chaos.Then again, would you prefer no electricity? ...

Core Insights - PulteGroup Inc. reported better-than-expected second-quarter 2024 results, with adjusted earnings and total revenues exceeding the Zacks Consensus Estimate [1][3]. Financial Performance - Adjusted earnings were $3.03 per share, surpassing the Zacks Consensus Estimate of $2.92 by 3.8%, but down from $3.58 in the same quarter last year [3]. - Total revenues reached $4.4 billion, exceeding the consensus mark of $4.37 billion by 0.8%, but decreased 4.3% from $4.6 billion year-over-year [3]. Segment Analysis - Homebuilding segment revenues fell 4.1% year-over-year to $4.3 billion, with home sale revenues also down 4.1% to $4.27 billion [4]. - The number of homes closed decreased by 5.7% to 7,639 units, while the average selling price (ASP) of homes delivered increased by 1.8% to $559,000 [5]. - Net new home orders declined 7.4% year-over-year to 7,083 units, with the value of new orders down 10.8% to $3.89 billion [5][6]. Backlog and Margins - The backlog of homes yet to be closed was 10,779 units, down from 12,982 units a year ago, with potential housing revenues from the backlog decreasing to $6.84 billion from $8.11 billion [6]. - Home sales gross margin decreased by 290 basis points year-over-year to 27%, while SG&A expenses as a percentage of home sales revenues increased by 100 basis points to 9.1% [6]. Financial Services - Revenues from the Financial Services segment dropped 9.4% year-over-year to $101.2 million, with pretax income declining to $43 million from $63 million a year ago [7]. Cash Position - At the end of the second quarter, cash, cash equivalents, and restricted cash totaled $1.27 billion, down from $1.65 billion at the end of 2024 [8]. - Net cash provided by operating activities was $421.7 million, down from $657.3 million in the prior-year period [9]. Market Outlook - CEO Ryan Marshall highlighted challenges in the spring selling season due to high mortgage rates and economic uncertainty, but noted improved consumer sentiment during periods of rate declines [2].

Ozzy Osbourne, the self-styled Prince of Darkness who helped define heavy-metal music as the singer of Black Sabbath, has died at age 76 https://t.co/lG3H3c6zwl ...

How To Stay Focused At Work When Everything Feels Uncertain https://t.co/ktH3GaErxD https://t.co/ktH3GaErxD ...

Tim Spence, chairman, CEO & president of Fifth Third Bank, joins "Open Interest" to discuss the impact stablecoin technology will have on the bank's operations. Congress delivered a watershed victory for the crypto industry last Thursday, passing the first federal legislation to regulate stablecoins and clearing the way for broader use of the technology in everyday finance http://bloom.bg/3GNlHBZ ...

Key Takeaways Block jumped 24.7% in a month, outperforming its industry's 5.7% gain and rising 7.2% intraday yesterday. SBlock, Inc. (XYZ) shares have surged 24.7% in a month, outperforming its industry’s rise of 5.7%. Notably, XYZ shares gained 7.2% during the intra-day trading session yesterday, after Block had made it to the coveted S&P 500 list.On Friday, July 18, S&P Dow Jones Indices announced that it will add Block to the S&P 500 Index, replacing Hess, which is set to be acquired by Chevron. The cha ...

主要为中小型生物技术公司提供临床研发外包服务的美国合同研究组织（CRO）Medpace刚刚公布的财报业绩强劲，股价大 涨。 EBITDA：二季度息税折旧摊销前利润（EBITDA）为1.305亿美元，同比增长16.2%，EBITDA利润率为21.6%，一 季度EBITDA同比增长2.6%、EBITDA利润率为21.2%。 2）业绩指引： 美东时间7月22日周二，Medpace股价（MEDP）跳空高开逾44%，早盘涨幅一度扩大到62.3%，后涨幅有所收窄，早盘尾声时 涨超50%，势将创收盘最高纪录，并创上市将近九年来最大单日涨幅。 Medpace股价暴涨也带飞了CRO概念股。周二美股早盘尾声时，Iqvia Holdings（IQV）涨近20%，ICLR PLC（ICLR）涨超 10%，Charles River Laboratories International（CRL）早盘曾涨超10%。 股价大涨前，本周一美股盘后，Medpace公布截至6月30日的公司第二季度财务业绩，并能提供以及2025年全年的业绩指引。 1）主要财务数据： 营收：二季度营收6.033亿美元，同比增长14.2%，分析师预期5.42亿美元， ...

Summary of Oncolytics Biotech Key Opinion Leader Webinar Company and Industry - **Company**: Oncolytics Biotech - **Industry**: Oncology, specifically focusing on pancreatic cancer and other gastrointestinal cancers Core Points and Arguments 1. **Introduction of Pelareorep**: Pelareorep is an oncolytic virus that selectively targets cancer cells and is administered intravenously, making it easier for widespread application compared to other oncolytic viruses that require intratumoral administration [6][7][8] 2. **Efficacy in Pancreatic Cancer**: Pelareorep has shown strong efficacy signals in pancreatic cancer, with a 62% overall response rate observed in clinical studies, which is significantly higher than traditional chemotherapy combinations [15][34] 3. **Unmet Need in Pancreatic Cancer**: Pancreatic cancer is the 10th most common cancer but the second leading cause of cancer death, highlighting the urgent need for effective treatments [10][11] 4. **Current Treatment Landscape**: Standard treatments include gemcitabine and FOLFIRINOX, with limited overall survival rates. Pelareorep combined with chemotherapy has shown improved survival rates compared to historical controls [12][13][22] 5. **Safety Profile**: Over 1,100 patients have been treated with Pelareorep, showing a favorable safety profile with mild side effects such as flu-like symptoms, indicating it is well-tolerated [66][70] 6. **Combination Therapy Potential**: Pelareorep can be combined with various chemotherapy regimens and checkpoint inhibitors, enhancing its therapeutic potential across multiple cancer types [86] 7. **Goblet Trial**: The Goblet trial is a significant study evaluating Pelareorep in combination with gemcitabine, nab-paclitaxel, and atezolizumab, showing promising early results [34][35] 8. **Biomarker Insights**: Tumor-infiltrating lymphocyte expansion has been identified as a potential biomarker correlating with treatment response, suggesting a mechanism of action that enhances immune response [40][41] Other Important but Possibly Overlooked Content 1. **Durability of Response**: The durability of responses in patients treated with Pelareorep is a notable characteristic, indicating potential long-term benefits [15] 2. **Mechanism of Action**: Pelareorep induces endoplasmic reticulum stress in pancreatic cancer cells, leading to apoptosis, which supports its mechanism of action [20] 3. **Future Directions**: There is a strong interest in exploring Pelareorep in registration-enabling studies for first-line treatment in pancreatic cancer, given the promising efficacy and safety data [57][69] 4. **Cross-Tumor Potential**: Pelareorep has demonstrated efficacy across various tumor types, including breast and colorectal cancers, indicating its potential as a versatile therapeutic agent [86] This summary encapsulates the key insights and discussions from the Oncolytics Biotech webinar, focusing on the promising role of Pelareorep in treating pancreatic cancer and its potential applications in other cancers.